Call MEDISCA now at 1-800-932-10391-800-665-6334

MEDISCA News at Your Fingertips

Medisca Acquires all IP assets of Maxima Pharmaceuticals Including the DIFFUSIMAX® Brand


On May 31, 2022, Medisca, a global supplier of pharmaceutical compounding products, acquired DIFFUSIMAX® and DIFFUSIMAX®10 liposomal bases (pluronic lecithin organogel or PLO gel), products used for preparing compounded topical formulations, as well as all intellectual property assets of Maxima Pharmaceuticals.

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA


MONTREAL, Q.C. (May 26, 2022) – On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio).

Medisca Pledges Another $100,000 in Matching Donations to the Alliance for Pharmacy Compounding Media Campaign Fund to Secure Compounded Hormone Therapy.


PLATTSBURGH, N.Y. (March 25, 2022) – Less than a year later, Medisca is back to pledge another $100,000 in matching donations to the Alliance for Pharmacy Compounding (APC) Media Campaign Fund, a three-year initiative to secure compounded hormone therapy through media and congressional engagement.

Medisca Signs Deal as Exclusive Global Distributor outside the USA & Israel for the Padagis Line of ORA Products


MONTREAL, Q.C. (January 12, 2022) – On December 9, 2021, Medisca entered into an exclusive global manufacture, supply, license and distribution agreement with Padagis (formerly, the Rx Division of Perrigo) for their ORA Product Line consisting of the following Padagis products in finished form ORA-Plus®, ORA-Sweet®, ORA-Sweet® SF, ORA-Blend®, and ORA-Blend® SF.

MEDISCA and fellow industry leaders lobby for revisions to compounded expiry dates and succeed


Over the last several months, MEDISCA Australia along with other industry leaders have been actively putting forward to the Australian Pharmaceutical Formulary & Handbook (APF), scientific rationale for longer expiry dates for compounded preparations. Medisca is now pleased to see the efforts of the compounding community come to fruition.

Medisca Removes Potential Allergens from Topical Products and Provides Essential BUD Testing to Support Clients


Medisca removes potential allergens from topical products and provides essential BUD testing to support clients.




We have placed cookies on your device to help make this website better.

We also use cookies to collect information for making reports and to help us improve the site. The cookies collect information in an anonymous form.

Copyright® 1989-2022 Medisca Inc.
All rights reserved